INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events... READ MORE

For US healthcare professionals

Heart-img

IN PATIENTS AT HIGH CV RISK
WITHOUT PRIOR MI OR STROKE

mega-phone
GraphGraph

SEE the Data on CV Risk Reduction in Patients at High CV Risk Without Prior MI or Stroke

Repatha® is now the first and only PCSK9i shown to reduce the risk of MACE in patients at high CV risk without prior MI or stroke2,3
Down Arrow IconDown Arrow Icon

VIEW CV Risk Reduction Outcomes for Patients With Established CVD

Repatha® plus a statin reduced the risk of CV events1,4
Map IconMap Icon

EXPLORE Broad Coverage and Affordability

Repatha® is covered for ~95% of insured patients5,†

>5

million patients

have received Repatha® worldwide5,‡

REVIEW SAFETY DATA
Have you seen
Amgen’s campaign?
Watch the commercial to learn what Repatha® can do for your patients
Have you seen
Amgen’s campaign?
Watch the commercial to learn what Repatha® can do for your patients

†Includes commercial, health exchange, Medicaid, and Medicare lives, as of September 2025, based on MMIT data. Inclusion on formulary does not imply superior clinical efficacy or safety. This information is subject to change without notice. For the most up-to-date and complete information regarding coverage of Repatha®, please contact the relevant payer directly. Individual insurance requirements may vary.

‡Cumulative post-market exposure estimates from July 2015 through July 2025, on patients that have received at least 1 dose (estimates assume administration) of the product, which was estimated using prescription claims data (IQVIA) for the U.S. and units distributed (Amgen Finance Electronic Data Warehouse) with average drug utilization patterns (MarketScan claims data) for all other regions. Utilization assumptions were applied to calculate the unique number of patients.

CHD = coronary heart disease; CV = cardiovascular; CVD = cardiovascular disease; IQVIA = IMS Quintiles Virtual Information Access; MI = myocardial infarction.

References: 1. Repatha® (evolocumab) Prescribing Information, Amgen. 2. Amgen. Repatha® now indicated for adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C. News release; August 25, 2025. 3. Bohula E, et al. Oral presentation presented at: American Heart Association; November 7-10, 2025; New Orleans, LA. 4. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. 5. Data on file, Amgen; 2025.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the FOURIER Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Indications

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.
  • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and in adults with heterozygous familial hypercholesterolemia (HeFH)

Please see full Prescribing Information.

Important Safety Information

Back To Top